Dr. Miguel-Angel Perales

Dr. Miguel-Angel Perales, MD, is a board-certified medical oncologist with specialized expertise in donor-derived hematopoietic stem cell transplantation. He focuses on the use of allogeneic stem cells to treat diseases of the blood and bone marrow, including leukemias and lymphomas. His clinical practice encompasses a broad range of hematologic malignancies, including acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma. His approach draws on multiple donor sources, including related and unrelated donors, as well as bone marrow, peripheral blood, and umbilical cord blood units, with stem cell modifications employed to enhance transplant effectiveness.

Dr. Perales is actively engaged in clinical and translational research aimed at improving outcomes for patients undergoing stem cell transplantation. He leads a clinical trial focused on patients with advanced and relapsed Hodgkin lymphoma, with the goal of identifying the safest way to perform allogeneic transplants in this population. His broader research program investigates strategies to reduce complications, relapse, and graft-versus-host disease. He and his colleagues are also exploring new agents such as interleukin-7 and KGF to accelerate immune recovery following transplantation, as well as novel methods for generating specialized T cells capable of targeting hematologic malignancies with greater precision.

Central to Dr. Perales's work is a commitment to expanding access to transplantation as a potentially curative therapy for all eligible patients. His translational research bridges laboratory discoveries with clinical application, advancing new immunological approaches to help the immune system fight blood cancers more effectively after transplant. Through his clinical trials and collaborative investigations, he continues to push the boundaries of what is possible in allogeneic stem cell transplantation, with a focus on safety, immune reconstitution, and long-term disease control for patients with hematologic malignancies.